Download PDF
Pharmacopsychiatry 2012; 45(01): 37-39
DOI: 10.1055/s-0031-1287776
Letter
© Georg Thieme Verlag KG Stuttgart · New York

A Case of Selective Mutism in an 8-Year-Old Girl with Thalassaemia Major after Bone Marrow Transplantation

P. L. Plener
1   Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany
,
S. A. Gatz
2   Department of Child and Adolescent Medicine, University of Ulm, Ulm, Germany
,
C. Schuetz
2   Department of Child and Adolescent Medicine, University of Ulm, Ulm, Germany
,
A. G. Ludolph
1   Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany
,
M. Kölch
1   Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany
› Author Affiliations
Further Information

Publication History

received 16 April 2011
revised 29 July 2011

accepted 01 August 2011

Publication Date:
11 October 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Selective mutism is rare with a prevalence below 1% in the general population, but a higher prevalence in populations at risk (children with speech retardation, migration). Evidence for treatment strategies is hardly available. This case report provides information on the treatment of selective mutism in an 8-year-old girl with preexisting thalassaemia major. As medications she received penicillin prophylaxis (500000 IE/d) and deferasirox (Exjade; 20–25mg/kg/d), an iron chelator. The preexisting somatic disease and treatment complicated the treatment, as there are no data about pharmacological combination therapy. Psychotherapy in day treatment, supported by the use of the SSRI fluoxetine (10 mg), led to a decrease in the selective mutism score from 33 to 12 points, GAF improved by 21 points. Mean levels of fluoxetine plus norfluoxetine were 287.8 ng/ml without significant level fluctuations.

Key words

mutism - SSRI - deferasirox - thalassaemia - fluoxetine
 

  • References

  • 1 Wong P. Selective mutism: a review of etiology, comorbidities, and treatment. Psychiatry 2010; 7: 23-31
    PubMedGoogle Scholar
  • 2 Kumpulainen K, Räsänen E, Raaska H et al. Selective mutism among second-graders in elementary school. Eur Child Adolesc Psychiatry 1998; 7: 24-29
    CrossrefPubMedGoogle Scholar
  • 3 Elizur Y, Perednik R. Prevalence and description of selective mutism in immigrant and native families: a controlled study. J Am Acad Child Adolesc Psychiatry 2003; 42: 1451-1459
    CrossrefPubMedGoogle Scholar
  • 4 Steinhausen HC, Juzi C. Elective mutism: an analysis of 100 cases. J Am Acad Child Adolesc Psychiatry 1996; 35: 606-614
    CrossrefPubMedGoogle Scholar
  • 5 Cohan SL, Chavira DA, Shipon-Blum E et al. Refining the classification of children with selective mutism: a latent profile analysis. J Clin Child Adolesc Psychol 2008; 37: 770-784
    PubMedGoogle Scholar
  • 6 Remschmidt H, Poller M, Herpertz-Dahlmann B et al. A follow-up study of 45 patients with elective mutism. Eur Arch Psychiatry Clin Neurosci 2001; 251: 284-296
    CrossrefPubMedGoogle Scholar
  • 7 Hartmann B, Lange M. Evaluationsbogen für das sozialinteraktive Kommunikationsverhalten bei Mutismus. 2006 available at http://www.boris-hartmann.de/sprachtherapie-boris-hartmann/files/evaluationsbogen.pdf
    PubMedGoogle Scholar
  • 8 Cohan SL, Chavira DA, Stein MB. Practicioner review: psychosocial interventions for children with selective mutism: a critical evaluation of the literature from 1990-2005. J Child PsycholPsychiatry 2006; 47: 1085-1097
    PubMedGoogle Scholar
  • 9 Kaakeh Y, Stumpf JL. Treatment of selective mutism: focus on selective serotonin reuptake inhibitors. Pharmacotherapy 2008; 28: 214-224
    CrossrefPubMedGoogle Scholar
  • 10 Galanello R, Piga A, Forni GL et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 2006; 91: 1343-1351
    PubMedGoogle Scholar